Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
- Conditions
- Upper Limb Essential Tremor (UL ET)
- Interventions
- Drug: Placebo for BOTOX
- Registration Number
- NCT05216250
- Lead Sponsor
- AbbVie
- Brief Summary
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating, and patients also experience associated social embarrassment. This study will assess how safe and effective BOTOX is in treating UL ET. Adverse events and change in disease activity will be evaluated.
BOTOX is an investigational drug being developed for the treatment of UL ET. Participants are randomly assigned to 1 of the 4 groups, called treatment arms. Each group receives different treatment. There is 1 in 2 chance that participants will be assigned to placebo. Around 174 participants, aged 18 to 80 years with UL ET will be enrolled in approximately 40 sites in North America.
Participants will receive BOTOX or placebo injections in Cycle 1 and Cycle 2. In Cycle 3, participants will receive unilateral or bilateral BOTOX injections. Each cycle is 12 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 174
-
Diagnosis of essential tremor in accordance with modified Tremor Investigation Group (TRIG) criteria as described in the protocol.
-
TREDS-Revised Scale (1-4 scale, whole numbers) unilateral score of >= 3 for the Tremor Disability Scale (TREDS) on any of the 7 unilateral items; no more than a single item score of 1 among the 7 unilateral items in the dominant limb.
-
TETRAS activities of daily living (ADL) (recorded on a 0-4 scale, whole numbers) minimum score of >= 3 on any of the 5 unilateral items; no more than a single item score of <=1 among the 5 unilateral items in the dominant limb.
-
At least one of the following criteria must also be met:
- TETRAS UL score (0-4 scale, with 0.5 increments) of > 2 in the dominant limb on at least one of the 3 maneuvers OR
- TETRAS Archimedes spiral task score (0-4 scale, with 0.5 increments) of > 2 in the dominant limb
- Any uncontrolled clinically significant medical condition other than the one under study.
- Any medical condition that may put the participant at increased risk with exposure to BOTOX Purified Neurotoxin Complex.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo/BOTOX Unilateral Placebo for BOTOX Participants will receive placebo in Cycle 1 and Cycle 2 followed by unilateral BOTOX in Cycle 3. Placebo/BOTOX Bilateral Placebo for BOTOX Participants will receive placebo in Cycle 1 and Cycle 2 followed by bilateral BOTOX in Cycle 3. BOTOX/BOTOX Unilateral BOTOX Participants will receive BOTOX in Cycle 1 and Cycle 2 and unilateral BOTOX in Cycle 3 BOTOX/BOTOX Bilateral BOTOX Participants will receive BOTOX in Cycle 1 and Cycle 2 and bilateral BOTOX in Cycle 3 Placebo/BOTOX Unilateral BOTOX Participants will receive placebo in Cycle 1 and Cycle 2 followed by unilateral BOTOX in Cycle 3. Placebo/BOTOX Bilateral BOTOX Participants will receive placebo in Cycle 1 and Cycle 2 followed by bilateral BOTOX in Cycle 3.
- Primary Outcome Measures
Name Time Method Number of Participants with Treatment Emergent Adverse Events (AEs) Up to approximately 36 weeks An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Change From Baseline in Tremor Disability Scale-Revised (TREDS-R) Total Score Across 7 Unilateral Items Week 24 Tremor Disability Scale-Revised (TREDS-R) is a scale to assess activities of daily living (ADL) through a self-questionnaire asking participants to rate how easy or difficult it is to perform a particular activity. The scale consists of 20 items with each item rated on a scale of 1 (able to do the activity without difficulty) to 4 (cannot do the activity by yourself). 7 items included in this subset will be: use a spoon to drink soup, hold a cup of tea, pour milk from a bottle or carton, dial a telephone, pick up your change in a shop, insert an electric plug into a socket, unlock your front door with a key.
- Secondary Outcome Measures
Name Time Method Change From Baseline in TETRAS Activity of Daily Living (TETRAS ADL) Total Score Across 5 Unilateral Items Week 24 TETRAS Activity of Daily Living (TETRAS ADL) is a clinical rating scale using the total score across 5 unilateral items of the analyzed 10-item TETRAS ADL, with each item's recorded scores of 0 and 1 (0-4 scale) combined into one category with a score of 1 for analysis on a 1-4 scale.
The 5 tasks included in this subset will be feeding with a spoon, drinking from a glass, pouring, using keys, and writing.Change From Baseline in TETRAS Handwriting Score Week 24 TETRAS Handwriting is an item of the TETRAS performance subscale that is designed to assess tremor severity. During this test, participants are instructed to write the standard sentence "This is a sample of my best handwriting" using the dominant hand only, which is then scored from 0 to 4 with 1 being tremor is "slight: untidy due to tremor that is barely visible" and 4 being "severe: completely illegible."
Change From Baseline in Clinical Global Impression of Severity (CGI-S) Week 24 CGI-S is a single item used to measure the clinician's impression of the current severity of the patient's essential tremor. The measure uses a 5-point rating scale where "0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe."
Change From Baseline in Essential Tremor Rating Assessment (TETRAS UL) Score Week 24 TETRAS Upper Limb (UL) Scale is an item of the TETRAS performance subscale that is designed to assess upper limb tremor during three maneuvers: forward horizontal reach posture, lateral "wing beating" posture, and finger-nose-finger testing. Each maneuver is scored from 0 to 4, with 1 indicating a tremor amplitude that is "barely visible" and 4 indicating a tremor amplitude that is \>= 20 cm.
Change From Baseline in TETRAS Archimedes Spiral Score Week 24 Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) Archimedes Spiral is an item of the TETRAS performance subscale that is designed to assess tremor severity. During this test, participants are instructed to draw an unbroken spiral which is then scored from 0 to 4, with 1 being tremor is "barely visible" and 4 being "figure not recognizable."
Change From Baseline in Patient Global Impression of Severity (PGI-S) Week 24 PGI-S is a single item used to measure the participant's impression of severity of their essential tremor symptoms. The measure uses a 5-point rating scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.
Trial Locations
- Locations (40)
Accel Research Sites - Neurology and Neurodiagnostics of Alabama, LLC /ID# 240472
🇺🇸Hoover, Alabama, United States
Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 231731
🇺🇸Phoenix, Arizona, United States
University of Arizona /ID# 239781
🇺🇸Tucson, Arizona, United States
Loma Linda University /ID# 230905
🇺🇸Loma Linda, California, United States
University of Colorado - Anschutz Medical Campus /ID# 239869
🇺🇸Aurora, Colorado, United States
New England Institute for Clinical Research /ID# 238404
🇺🇸Stamford, Connecticut, United States
Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 231677
🇺🇸Boca Raton, Florida, United States
Coastal Clinical Research Specialists /ID# 240897
🇺🇸Fernandina Beach, Florida, United States
Coastal Clinical Research Specialists /ID# 240471
🇺🇸Jacksonville, Florida, United States
Charter Research - Winter Park /ID# 241568
🇺🇸Orlando, Florida, United States
CDC Research Institute LLC /ID# 242744
🇺🇸Port Saint Lucie, Florida, United States
Emory University / Emory Brain Health Center /ID# 231911
🇺🇸Atlanta, Georgia, United States
Accel Research Site-NeuroStudies /ID# 239881
🇺🇸Decatur, Georgia, United States
Univ Kansas Med Ctr /ID# 231166
🇺🇸Kansas City, Kansas, United States
Kansas Institute of Research /ID# 231623
🇺🇸Overland Park, Kansas, United States
Tufts Medical Center /ID# 239929
🇺🇸Boston, Massachusetts, United States
Lahey Hospital & Medical Center /ID# 233232
🇺🇸Burlington, Massachusetts, United States
Henry Ford Health Medical Center - Jackson /ID# 231400
🇺🇸Jackson, Michigan, United States
Dent Neurologic Institute - Amherst /ID# 255665
🇺🇸Amherst, New York, United States
UNC Hospitals Neurology Clinic - Chapel Hill /ID# 238857
🇺🇸Chapel Hill, North Carolina, United States
Neurology - Triad /ID# 239806
🇺🇸Winston-Salem, North Carolina, United States
Atrium Health Wake Forest Baptist Medical Center /ID# 233550
🇺🇸Winston-Salem, North Carolina, United States
Dayton Center for Neurological Disorders /ID# 233737
🇺🇸Centerville, Ohio, United States
The Orthopedic Foundation /ID# 232234
🇺🇸New Albany, Ohio, United States
Oregon Health and Science University /ID# 231581
🇺🇸Portland, Oregon, United States
Thomas Jefferson University Hospital /ID# 232614
🇺🇸Philadelphia, Pennsylvania, United States
University of Pittsburgh MC /ID# 233735
🇺🇸Pittsburgh, Pennsylvania, United States
Medical University of South Carolina /ID# 233538
🇺🇸Charleston, South Carolina, United States
Texas Neurology /ID# 250428
🇺🇸Dallas, Texas, United States
University of Texas Southwestern Medical Center /ID# 239770
🇺🇸Dallas, Texas, United States
Texas Movement Disorder Specialists, PLLC /ID# 242524
🇺🇸Georgetown, Texas, United States
Baylor College of Medicine /ID# 231624
🇺🇸Houston, Texas, United States
Univ Texas HSC San Antonio /ID# 232615
🇺🇸San Antonio, Texas, United States
Integrated Neurology Services - Falls Church /ID# 233545
🇺🇸Falls Church, Virginia, United States
Gamma Therapeutic Center /ID# 232547
🇺🇸Greenfield, Wisconsin, United States
Marshfield Clinic - Marshfield /ID# 233191
🇺🇸Marshfield, Wisconsin, United States
Vancouver Coastal Health Authority - University of British Columbia /ID# 240356
🇨🇦Vancouver, British Columbia, Canada
Centricity Research /ID# 240587
🇨🇦Halifax, Nova Scotia, Canada
Toronto Western Hospital /ID# 231587
🇨🇦Toronto, Ontario, Canada
Genge Partners /ID# 251546
🇨🇦Montreal, Quebec, Canada